Epithelial-mesenchymal transition (EMT) and its reverse, mesenchymal-epithelial transition (MET), are developmental programs that have been shown to play critical roles in promoting metastasis and invasion as well as contribute to drug resistance in carcinoma. ATCC has employed CRISPR/Cas9 gene editing to develop its first reporter line designed to enable the real-time monitoring of the changing status of cells from epithelial to mesenchymal.
- CRISPR/Cas9 gene-edited vimentin-RFP fusion protein
- Strong RFP signal upon vimentin induction
- Physiological E-cadherin expression in the absence of EMT
Increased invasive capacity following EMT
EMT sensitive to A83-01 and PP1 inhibition